These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21452417)

  • 1. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience.
    Harper SJ; Gelson W; Harper IG; Alexander GJ; Gibbs P
    Transplantation; 2011 Jan; 91(1):128-32. PubMed ID: 21452417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of conversion to sirolimus monotherapy after liver transplant.
    Uhlmann D; Weber T; Ludwig S; Ludwig B; Bartels M; Hauss J; Jonas S; Witzigmann H
    Exp Clin Transplant; 2012 Feb; 10(1):30-8. PubMed ID: 22309417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.
    Shah M; Shankar A; Gee I; Nash K; Hoare M; Gibbs P; Davies S; Alexander GJ
    Aliment Pharmacol Ther; 2015 Feb; 41(4):379-92. PubMed ID: 25496225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
    J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in liver transplant recipients: a large single-center experience.
    Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
    Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of cyclosporine to sirolimus before 12 months is associated with marked improvement in renal function and low proteinuria in a South African renal transplant population.
    Maharaj S; Assounga AG
    Exp Clin Transplant; 2010 Mar; 8(1):14-8. PubMed ID: 20199366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients.
    Li LC; Hsu CN; Lin CC; Cheng YF; Hu TH; Chen DW; Lee CH; Nakano T; Chen CL
    BMC Gastroenterol; 2017 Apr; 17(1):58. PubMed ID: 28427351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus and mycophenolate mofetil after liver transplantation.
    Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
    Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
    Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
    Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
    Groetzner J; Meiser B; Landwehr P; Buehse L; Mueller M; Kaczmarek I; Vogeser M; Daebritz S; Ueberfuhr P; Reichart B
    Transplantation; 2004 Feb; 77(4):568-74. PubMed ID: 15084937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is sirolimus responsible for proteinuria?
    Dervaux T; Caillard S; Meyer C; Ellero B; Woehl-Jaegle ML; Hannedouche T; Wolf P; Moulin B
    Transplant Proc; 2005; 37(6):2828-9. PubMed ID: 16182822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
    Nair S; Eason J; Loss G
    Liver Transpl; 2003 Feb; 9(2):126-9. PubMed ID: 12548505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.